New 20-Valent pneumonia vaccine shows promise in chinese seniors
NCT ID NCT07019909
First seen Nov 21, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This study tested a new 20-valent pneumococcal vaccine (20vPnC) in 400 Chinese adults aged 50 and older who had never received a pneumonia vaccine. The goal was to see if it is safe and triggers a strong immune response compared to the current 13-valent vaccine. Participants were monitored for side effects like pain, fever, and fatigue, and blood tests measured their immune reaction.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kaihua County Center For Disease Prevention and Control
Kaihua, Zhejiang, 324300, China
-
Kaihua County Center For Disease Prevention and Control
Quzhou, Zhejiang, 324300, China
-
Zhejiang provincial center for disease control and prevention
Hangzhou, Zhejiang, 310051, China
Conditions
Explore the condition pages connected to this study.